NDA 017443 · Ph Health
Dantrium
Dantrolene Sodium · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jul 8, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1974
Jan 15, 1974
Approved uses
1
Original approval plus efficacy supplements
Registered trials
12
4 Phase 3, 1 recruiting
FAERS reports
1,138
998 serious, 124 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
Dantrolene sodium has a potential for hepatotoxicity, and should not be used in conditions other than those recommended. Symptomatic hepatitis (fatal and non-fatal) has been reported at various dose levels of the drug. The incidence reported in patients taking up to 400 mg/day is much lower than in those taking doses of 800 mg or more per day. Even sporadic short courses of these higher dose levels within a treatment regimen markedly increased the risk of serious hepatic injury. Liver dysfunction as evidenced by blood chemical abnormalities alone (liver enzyme elevations) has been observed in patients exposed to dantrolene sodium for varying periods of time. Overt hepatitis has occurred at varying intervals after initiation of therapy, but has been most frequently observed between the third and twelfth month of therapy. The risk of hepatic injury appears to be greater in females, in...
What it is approved for
From the label in effect Nov 11, 2026.
INDICATIONS AND USAGE In Chronic Spasticity: Dantrolene sodium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrolene sodium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrolene sodium. Occasionally, subtle but meaningful improvement in spasticity may occur with dantrolene sodium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of dantrolene sodium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of dantrolene sodium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. In Malignant...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 15, 1974 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
- DANTRIUM · DANTROLENE SODIUM 50MG · CAPSULE, ORAL · Prescription · TE AB
- DANTRIUM · DANTROLENE SODIUM 25MG · CAPSULE, ORAL · Prescription · TE AB
- DANTRIUM · DANTROLENE SODIUM 100MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dantrolene" as an intervention, any sponsor and status, largest first.
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT03109288 · 250 participants (planned) · Start Aug 11, 2017 · Primary completion Jan 1, 2027
Drug: Cilostazol; Leucovorin and 3 more · For: Multiple Sclerosis
Sites: Bethesda, Maryland
- The Use of Dantrolene to Improve Analgesia in Posterior Lumbar SurgeryPivotal-lookingCompleted
Beth Israel Deaconess Medical CenterAcademic, hospital or other
NCT03762109 · 116 participants · Start Jul 29, 2019 · Primary completion Jun 1, 2024
Drug: Dantrolene; Placebo Oral Tablet · For: Lumbar Spine Injury
Sites: Boston, Massachusetts
- A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.Pivotal-lookingCompleted
Vanderbilt University Medical CenterAcademic, hospital or other
NCT04134845 · 68 participants · Start Aug 21, 2020 · Primary completion May 29, 2025
Drug: Dantrolene/Ryanodex; Placebo · For: Ventricular Tachycardia
Sites: Nashville, Tennessee
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT01950520 · 47 participants · Start Feb 7, 2014 · Primary completion Dec 17, 2022
Drug: Propranolol; Pindolol and 11 more · For: Healthy Volunteers
Sites: Bethesda, Maryland
- Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)Pivotal-lookingTerminated
Medical University of ViennaAcademic, hospital or other
NCT00796900 · 34 participants (planned) · Start May 2008 · Primary completion Mar 2011
Drug: Dantrolene; Placebo · For: Hyperthermia
Sites: Vienna, Austria
Eagle Pharmaceuticals, Inc.Industry
NCT02513095 · 34 participants · Start Sep 2015 · Primary completion Sep 2015
Drug: Dantrolene sodium for injectable suspension · For: Heat Stroke
Sites: Mecca, Saudi Arabia
University of Massachusetts, WorcesterAcademic, hospital or other
NCT01024972 · 31 participants · Start Oct 2009 · Primary completion Jul 2013
Drug: Dantrolene; Placebo · For: Subarachnoid Hemorrhage; Cerebral Vasospasm
Sites: Worcester, Massachusetts
- Dantrolene in Statin-induced MyopathyPivotal-lookingNot yet recruiting
Tanta UniversityAcademic, hospital or other
NCT06966843 · 23 participants (planned) · Start Oct 2027 · Primary completion Jan 2029
Drug: Dantrolene; Placebo · For: Statins Induced Myopathy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neuroleptic malignant syndrome79
- pyrexia63
- pneumonia61
- asthenia59
- drug ineffective59
- respiratory failure59
- off label use54
- urinary tract infection52
- vomiting52
- diarrhoea49
- muscular weakness45
- nausea45
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 45 |
| 2005 | 47 |
| 2006 | 54 |
| 2007 | 49 |
| 2008 | 59 |
| 2009 | 62 |
| 2010 | 61 |
| 2011 | 81 |
| 2012 | 83 |
| 2013 | 73 |
| 2014 | 43 |
| 2015 | 46 |
| 2016 | 63 |
| 2017 | 57 |
| 2018 | 45 |
| 2019 | 53 |
| 2020 | 42 |
| 2021 | 31 |
| 2022 | 36 |
| 2023 | 35 |
| 2024 | 27 |
| 2025 | 30 |
| 2026 | 16 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dantrium (Dantrolene Sodium)
2024 spending
$8K
Beneficiaries
n/a
39 claims
Per beneficiary
n/a
$1.02 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $29,516 |
| 2021 | $26,804 |
| 2022 | $17,162 |
| 2023 | $9,844 |
| 2024 | $7,941 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
Chou R, Peterson K, Helfand M · J Pain Symptom Manage 2004 · Comparative Study, Evaluation Study
- Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Boggild M, Young C · Cochrane Database Syst Rev 2001 · Systematic Review
- Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Young CA, Boggild M · Cochrane Database Syst Rev 2000 · Systematic Review
- Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Boggild M, Young C · Cochrane Database Syst Rev 2003 · Systematic Review
- Myoplasmic Ca2+ concentration during exertional rhabdomyolysis.
López JR, Rojas B, Gonzalez MA, et al. · Lancet 1995 · Clinical Trial, Controlled Clinical Trial
- The novel rapid formulation of intravenous dantrolene (NPJ5008) versus standard dantrolene (Dantrium®): A clinical part-randomised phase 1 study in healthy volunteers.
Ng Kwet Shing RH, Clayton LB, Smith SL, et al. · Eur J Anaesthesiol 2024 · Randomized Controlled Trial, Clinical Trial, Phase I
Sponsor: Ph Health
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.